Global Generic Drugs Sales 麻豆原创 Report 2023

Publication ID:

PB501238176

Publication Date:

January 4, 2023

Pages:

138

Publisher:

MRRPB5

Countries:

Global [1]

USD 4,000.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.
麻豆原创 Analysis and Insights: Global Generic Drugs 麻豆原创
Due to the COVID-19 pandemic, the global Generic Drugs market size is estimated to be worth US$ 313470 million in 2022 and is forecast to a readjusted size of US$ 551330 million by 2029 with a CAGR of 8.3% during the forecast period 2023-2029. Fully considering the economic change by this health crisis, Prescription accounting for % of the Generic Drugs global market in 2022, is projected to value US$ million by 2029, growing at a revised % CAGR from 2023 to 2029. While Hospital segment is altered to an % CAGR throughout this forecast period.
麻豆原创 competition is not intense. Teva, Novartis 鈥� Sandoz, Mylan, Sun Pharmaceutical and Aspen are the leaders of the industry, with about 19% market shares.
North America is the largest consumption place, with a consumption market share nearly 44%. Following North America, Europe is the second largest consumption place with the consumption market share of 18%.
Global Generic Drugs Scope and 麻豆原创 Size
The global Generic Drugs market is segmented by company, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Generic Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2018-2029.
Segment by Type
Prescription
Non-Prescription Drugs
Segment by Application
Hospital
Clinic
Others
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Teva
Novartis - Sandoz
Mylan
Sun Pharmaceutical
Aspen
Fresenius Kabi
Pfizer (Hospira)
Sanofi
Aurobindo
Lupin
Dr. Reddy's
Apotex
Cipla
ENDO (Par Pharmaceutical)
Stada Arzneimittel
Krka Group
Nichi-Iko Pharmaceutical
Valeant
Zydus Cadila
Hikma
Pharmaniaga Berhad
Hovid Berhad
Duopharma Biotech
Kotra Pharma
HOE Pharmaceutical
Y.S.P. Industries

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Generic Drugs 麻豆原创 Size by Type (2018 VS 2022 VS 2029)
1.2.2 Prescription
1.2.3 Non-Prescription Drugs
1.3 麻豆原创 by Application
1.3.1 Global Generic Drugs 麻豆原创 Share by Application (2018 VS 2022 VS 2029)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Generic Drugs 麻豆原创 Perspective (2018-2029)
2.2 Global Generic Drugs 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.3 Global Generic Drugs Revenue 麻豆原创 Share by Region (2018-2023)
2.4 Global Generic Drugs Revenue Forecast by Region (2024-2029)
2.5 Geographic 麻豆原创 Analysis: 麻豆原创 Facts & Figures
2.5.1 United States Generic Drugs Estimates and Projections (2018-2029)
2.5.2 Europe Generic Drugs Estimates and Projections (2018-2029)
2.5.3 China Generic Drugs Estimates and Projections (2018-2029)
2.5.4 Japan Generic Drugs Estimates and Projections (2018-2029)
2.5.5 Southeast Asia Generic Drugs Estimates and Projections (2018-2029)
2.5.6 India Generic Drugs Estimates and Projections (2018-2029)
3 Global Generic Drugs Competition Landscape by Players
3.1 Global Top Generic Drugs Players by Revenue (2018-2023)
3.1.1 Global Top Generic Drugs Players by Revenue (2018-2023)
3.1.2 Global Generic Drugs Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Generic Drugs 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Generic Drugs Revenue
3.4 Global Generic Drugs 麻豆原创 Concentration Ratio
3.4.1 Global Generic Drugs 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Generic Drugs Revenue in 2022
3.5 Generic Drugs Key Players Head office and Area Served
3.6 Key Players Generic Drugs Product Solution and Service
3.7 Date of Enter into Generic Drugs 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Generic Drugs Breakdown Data by Type
4.1 Global Generic Drugs Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Generic Drugs Forecasted 麻豆原创 Size by Type (2024-2029)
5 Generic Drugs Breakdown Data by Application
5.1 Global Generic Drugs Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Generic Drugs Forecasted 麻豆原创 Size by Application (2024-2029)
6 United States Generic Drugs 麻豆原创 Facts & Figures
6.1 United States Generic Drugs Revenue by Company (2018-2023)
6.2 United States Generic Drugs 麻豆原创 Size by Type
6.2.1 United States Generic Drugs 麻豆原创 Size by Type (2018-2023)
6.2.2 United States Generic Drugs 麻豆原创 Size by Type (2024-2029)
6.2.3 United States Generic Drugs 麻豆原创 Share by Type (2018-2029)
6.3 United States Generic Drugs 麻豆原创 Size by Application
6.3.1 United States Generic Drugs 麻豆原创 Size by Application (2018-2023)
6.3.2 United States Generic Drugs 麻豆原创 Size by Application (2024-2029)
6.3.3 United States Generic Drugs 麻豆原创 Share by Application (2018-2029)
7 Europe Generic Drugs 麻豆原创 Facts & Figures
7.1 Europe Generic Drugs Revenue by Company (2018-2023)
7.2 Europe Generic Drugs 麻豆原创 Size by Type
7.2.1 Europe Generic Drugs 麻豆原创 Size by Type (2018-2023)
7.2.2 Europe Generic Drugs 麻豆原创 Size by Type (2024-2029)
7.2.3 Europe Generic Drugs 麻豆原创 Share by Type (2018-2029)
7.3 Europe Generic Drugs 麻豆原创 Size by Application
7.3.1 Europe Generic Drugs 麻豆原创 Size by Application (2018-2023)
7.3.2 Europe Generic Drugs 麻豆原创 Size by Application (2024-2029)
7.3.3 Europe Generic Drugs 麻豆原创 Share by Application (2018-2029)
8 China Generic Drugs 麻豆原创 Facts & Figures
8.1 China Generic Drugs Revenue by Company (2018-2023)
8.2 China Generic Drugs 麻豆原创 Size by Type
8.2.1 China Generic Drugs 麻豆原创 Size by Type (2018-2023)
8.2.2 China Generic Drugs 麻豆原创 Size by Type (2024-2029)
8.2.3 China Generic Drugs 麻豆原创 Share by Type (2018-2029)
8.3 China Generic Drugs 麻豆原创 Size by Application
8.3.1 China Generic Drugs 麻豆原创 Size by Application (2018-2023)
8.3.2 China Generic Drugs 麻豆原创 Size by Application (2024-2029)
8.3.3 China Generic Drugs 麻豆原创 Share by Application (2018-2029)
9 Japan Generic Drugs 麻豆原创 Facts & Figures
9.1 Japan Generic Drugs Revenue by Company (2018-2023)
9.2 Japan Generic Drugs 麻豆原创 Size by Type
9.2.1 Japan Generic Drugs 麻豆原创 Size by Type (2018-2023)
9.2.2 Japan Generic Drugs 麻豆原创 Size by Type (2024-2029)
9.2.3 Japan Generic Drugs 麻豆原创 Share by Type (2018-2029)
9.3 Japan Generic Drugs 麻豆原创 Size by Application
9.3.1 Japan Generic Drugs 麻豆原创 Size by Application (2018-2023)
9.3.2 Japan Generic Drugs 麻豆原创 Size by Application (2024-2029)
9.3.3 Japan Generic Drugs 麻豆原创 Share by Application (2018-2029)
10 Southeast Asia Generic Drugs 麻豆原创 Facts & Figures
10.1 Southeast Asia Generic Drugs Revenue by Company (2018-2023)
10.2 Southeast Asia Generic Drugs 麻豆原创 Size by Type
10.2.1 Southeast Asia Generic Drugs 麻豆原创 Size by Type (2018-2023)
10.2.2 Southeast Asia Generic Drugs 麻豆原创 Size by Type (2024-2029)
10.2.3 Southeast Asia Generic Drugs 麻豆原创 Share by Type (2018-2029)
10.3 Southeast Asia Generic Drugs 麻豆原创 Size by Application
10.3.1 Southeast Asia Generic Drugs 麻豆原创 Size by Application (2018-2023)
10.3.2 Southeast Asia Generic Drugs 麻豆原创 Size by Application (2024-2029)
10.3.3 Southeast Asia Generic Drugs 麻豆原创 Share by Application (2018-2029)
11 India Generic Drugs 麻豆原创 Facts & Figures
11.1 India Generic Drugs Revenue by Company (2018-2023)
11.2 India Generic Drugs 麻豆原创 Size by Type
11.2.1 India Generic Drugs 麻豆原创 Size by Type (2018-2023)
11.2.2 India Generic Drugs 麻豆原创 Size by Type (2024-2029)
11.2.3 India Generic Drugs 麻豆原创 Share by Type (2018-2029)
11.3 India Generic Drugs 麻豆原创 Size by Application
11.3.1 India Generic Drugs 麻豆原创 Size by Application (2018-2023)
11.3.2 India Generic Drugs 麻豆原创 Size by Application (2024-2029)
11.3.3 India Generic Drugs 麻豆原创 Share by Application (2018-2029)
12 Key Players Profiles
12.1 Teva
12.1.1 Teva Company Details
12.1.2 Teva Business Overview
12.1.3 Teva Generic Drugs Introduction
12.1.4 Teva Revenue in Generic Drugs Business (2018-2023)
12.1.5 Teva Recent Development
12.2 Novartis - Sandoz
12.2.1 Novartis - Sandoz Company Details
12.2.2 Novartis - Sandoz Business Overview
12.2.3 Novartis - Sandoz Generic Drugs Introduction
12.2.4 Novartis - Sandoz Revenue in Generic Drugs Business (2018-2023)
12.2.5 Novartis - Sandoz Recent Development
12.3 Mylan
12.3.1 Mylan Company Details
12.3.2 Mylan Business Overview
12.3.3 Mylan Generic Drugs Introduction
12.3.4 Mylan Revenue in Generic Drugs Business (2018-2023)
12.3.5 Mylan Recent Development
12.4 Sun Pharmaceutical
12.4.1 Sun Pharmaceutical Company Details
12.4.2 Sun Pharmaceutical Business Overview
12.4.3 Sun Pharmaceutical Generic Drugs Introduction
12.4.4 Sun Pharmaceutical Revenue in Generic Drugs Business (2018-2023)
12.4.5 Sun Pharmaceutical Recent Development
12.5 Aspen
12.5.1 Aspen Company Details
12.5.2 Aspen Business Overview
12.5.3 Aspen Generic Drugs Introduction
12.5.4 Aspen Revenue in Generic Drugs Business (2018-2023)
12.5.5 Aspen Recent Development
12.6 Fresenius Kabi
12.6.1 Fresenius Kabi Company Details
12.6.2 Fresenius Kabi Business Overview
12.6.3 Fresenius Kabi Generic Drugs Introduction
12.6.4 Fresenius Kabi Revenue in Generic Drugs Business (2018-2023)
12.6.5 Fresenius Kabi Recent Development
12.7 Pfizer (Hospira)
12.7.1 Pfizer (Hospira) Company Details
12.7.2 Pfizer (Hospira) Business Overview
12.7.3 Pfizer (Hospira) Generic Drugs Introduction
12.7.4 Pfizer (Hospira) Revenue in Generic Drugs Business (2018-2023)
12.7.5 Pfizer (Hospira) Recent Development
12.8 Sanofi
12.8.1 Sanofi Company Details
12.8.2 Sanofi Business Overview
12.8.3 Sanofi Generic Drugs Introduction
12.8.4 Sanofi Revenue in Generic Drugs Business (2018-2023)
12.8.5 Sanofi Recent Development
12.9 Aurobindo
12.9.1 Aurobindo Company Details
12.9.2 Aurobindo Business Overview
12.9.3 Aurobindo Generic Drugs Introduction
12.9.4 Aurobindo Revenue in Generic Drugs Business (2018-2023)
12.9.5 Aurobindo Recent Development
12.10 Lupin
12.10.1 Lupin Company Details
12.10.2 Lupin Business Overview
12.10.3 Lupin Generic Drugs Introduction
12.10.4 Lupin Revenue in Generic Drugs Business (2018-2023)
12.10.5 Lupin Recent Development
12.11 Dr. Reddy's
12.11.1 Dr. Reddy's Company Details
12.11.2 Dr. Reddy's Business Overview
12.11.3 Dr. Reddy's Generic Drugs Introduction
12.11.4 Dr. Reddy's Revenue in Generic Drugs Business (2018-2023)
12.11.5 Dr. Reddy's Recent Development
12.12 Apotex
12.12.1 Apotex Company Details
12.12.2 Apotex Business Overview
12.12.3 Apotex Generic Drugs Introduction
12.12.4 Apotex Revenue in Generic Drugs Business (2018-2023)
12.12.5 Apotex Recent Development
12.13 Cipla
12.13.1 Cipla Company Details
12.13.2 Cipla Business Overview
12.13.3 Cipla Generic Drugs Introduction
12.13.4 Cipla Revenue in Generic Drugs Business (2018-2023)
12.13.5 Cipla Recent Development
12.14 ENDO (Par Pharmaceutical)
12.14.1 ENDO (Par Pharmaceutical) Company Details
12.14.2 ENDO (Par Pharmaceutical) Business Overview
12.14.3 ENDO (Par Pharmaceutical) Generic Drugs Introduction
12.14.4 ENDO (Par Pharmaceutical) Revenue in Generic Drugs Business (2018-2023)
12.14.5 ENDO (Par Pharmaceutical) Recent Development
12.15 Stada Arzneimittel
12.15.1 Stada Arzneimittel Company Details
12.15.2 Stada Arzneimittel Business Overview
12.15.3 Stada Arzneimittel Generic Drugs Introduction
12.15.4 Stada Arzneimittel Revenue in Generic Drugs Business (2018-2023)
12.15.5 Stada Arzneimittel Recent Development
12.16 Krka Group
12.16.1 Krka Group Company Details
12.16.2 Krka Group Business Overview
12.16.3 Krka Group Generic Drugs Introduction
12.16.4 Krka Group Revenue in Generic Drugs Business (2018-2023)
12.16.5 Krka Group Recent Development
12.17 Nichi-Iko Pharmaceutical
12.17.1 Nichi-Iko Pharmaceutical Company Details
12.17.2 Nichi-Iko Pharmaceutical Business Overview
12.17.3 Nichi-Iko Pharmaceutical Generic Drugs Introduction
12.17.4 Nichi-Iko Pharmaceutical Revenue in Generic Drugs Business (2018-2023)
12.17.5 Nichi-Iko Pharmaceutical Recent Development
12.18 Valeant
12.18.1 Valeant Company Details
12.18.2 Valeant Business Overview
12.18.3 Valeant Generic Drugs Introduction
12.18.4 Valeant Revenue in Generic Drugs Business (2018-2023)
12.18.5 Valeant Recent Development
12.19 Zydus Cadila
12.19.1 Zydus Cadila Company Details
12.19.2 Zydus Cadila Business Overview
12.19.3 Zydus Cadila Generic Drugs Introduction
12.19.4 Zydus Cadila Revenue in Generic Drugs Business (2018-2023)
12.19.5 Zydus Cadila Recent Development
12.20 Hikma
12.20.1 Hikma Company Details
12.20.2 Hikma Business Overview
12.20.3 Hikma Generic Drugs Introduction
12.20.4 Hikma Revenue in Generic Drugs Business (2018-2023)
12.20.5 Hikma Recent Development
12.21 Pharmaniaga Berhad
12.21.1 Pharmaniaga Berhad Company Details
12.21.2 Pharmaniaga Berhad Business Overview
12.21.3 Pharmaniaga Berhad Generic Drugs Introduction
12.21.4 Pharmaniaga Berhad Revenue in Generic Drugs Business (2018-2023)
12.21.5 Pharmaniaga Berhad Recent Development
12.22 Hovid Berhad
12.22.1 Hovid Berhad Company Details
12.22.2 Hovid Berhad Business Overview
12.22.3 Hovid Berhad Generic Drugs Introduction
12.22.4 Hovid Berhad Revenue in Generic Drugs Business (2018-2023)
12.22.5 Hovid Berhad Recent Development
12.23 Duopharma Biotech
12.23.1 Duopharma Biotech Company Details
12.23.2 Duopharma Biotech Business Overview
12.23.3 Duopharma Biotech Generic Drugs Introduction
12.23.4 Duopharma Biotech Revenue in Generic Drugs Business (2018-2023)
12.23.5 Duopharma Biotech Recent Development
12.24 Kotra Pharma
12.24.1 Kotra Pharma Company Details
12.24.2 Kotra Pharma Business Overview
12.24.3 Kotra Pharma Generic Drugs Introduction
12.24.4 Kotra Pharma Revenue in Generic Drugs Business (2018-2023)
12.24.5 Kotra Pharma Recent Development
12.25 HOE Pharmaceutical
12.25.1 HOE Pharmaceutical Company Details
12.25.2 HOE Pharmaceutical Business Overview
12.25.3 HOE Pharmaceutical Generic Drugs Introduction
12.25.4 HOE Pharmaceutical Revenue in Generic Drugs Business (2018-2023)
12.25.5 HOE Pharmaceutical Recent Development
12.26 Y.S.P. Industries
12.26.1 Y.S.P. Industries Company Details
12.26.2 Y.S.P. Industries Business Overview
12.26.3 Y.S.P. Industries Generic Drugs Introduction
12.26.4 Y.S.P. Industries Revenue in Generic Drugs Business (2018-2023)
12.26.5 Y.S.P. Industries Recent Development
13 麻豆原创 Dynamics
13.1 Generic Drugs Industry Trends
13.2 Generic Drugs 麻豆原创 Drivers
13.3 Generic Drugs 麻豆原创 Challenges
13.4 Generic Drugs 麻豆原创 Restraints
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author List
15.3 Disclaimer

Companies Mentioned:

Teva
Novartis - Sandoz
Mylan
Sun Pharmaceutical
Aspen
Fresenius Kabi
Pfizer (Hospira)
Sanofi
Aurobindo
Lupin
Dr. Reddy's
Apotex
Cipla
ENDO (Par Pharmaceutical)
Stada Arzneimittel
Krka Group
Nichi-Iko Pharmaceutical
Valeant
Zydus Cadila
Hikma
Pharmaniaga Berhad
Hovid Berhad
Duopharma Biotech
Kotra Pharma
HOE Pharmaceutical
Y.S.P. Industries

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.